Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion

Paul E Fenster, Keith A. Comess, Randall Marsh, Charles Katzenberg, W. David Hager

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

We evaluated the efficacy of an intravenous infusion of procainamide in 26 consecutive candidates for cardioversion of atrial fibrillation. Procainamide was administered at a rate of 15 to 20 mg/min up to a maximum of 1000 mg. The treatment was considered effective only if cardioversion occurred during the procainamide infusion. Conversion to sinus rhythm occurred in 15 patients. Converters had a significantly shorter mean duration of atrial fibrillation (6 ± 7 days, mean ± S.D.) compared to nonconverters (79 ± 88 days) (p < 0.01). The mean left atrial size of converters (4.3 ± 0.6 cm) did not differ significantly from that of nonconverters (4.7 ± 0.9 cm). The dose of procainamide required for cardioversion ranged from 3.6 to 16.4 mg/kg. Two patients developed nonsustained ventricular tachycardia, and there was one episode of bifascicular block during the infusion. Intravenous procainamide is an effective form of therapy for conversion of atrial fibrillation of new onset.

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalAmerican Heart Journal
Volume106
Issue number3
DOIs
StatePublished - 1983

Fingerprint

Procainamide
Intravenous Infusions
Atrial Fibrillation
Electric Countershock
Ventricular Tachycardia
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. / Fenster, Paul E; Comess, Keith A.; Marsh, Randall; Katzenberg, Charles; Hager, W. David.

In: American Heart Journal, Vol. 106, No. 3, 1983, p. 501-504.

Research output: Contribution to journalArticle

Fenster, Paul E ; Comess, Keith A. ; Marsh, Randall ; Katzenberg, Charles ; Hager, W. David. / Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. In: American Heart Journal. 1983 ; Vol. 106, No. 3. pp. 501-504.
@article{92890a2c6b8e4bc3aa4db6a7b31b701f,
title = "Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion",
abstract = "We evaluated the efficacy of an intravenous infusion of procainamide in 26 consecutive candidates for cardioversion of atrial fibrillation. Procainamide was administered at a rate of 15 to 20 mg/min up to a maximum of 1000 mg. The treatment was considered effective only if cardioversion occurred during the procainamide infusion. Conversion to sinus rhythm occurred in 15 patients. Converters had a significantly shorter mean duration of atrial fibrillation (6 ± 7 days, mean ± S.D.) compared to nonconverters (79 ± 88 days) (p < 0.01). The mean left atrial size of converters (4.3 ± 0.6 cm) did not differ significantly from that of nonconverters (4.7 ± 0.9 cm). The dose of procainamide required for cardioversion ranged from 3.6 to 16.4 mg/kg. Two patients developed nonsustained ventricular tachycardia, and there was one episode of bifascicular block during the infusion. Intravenous procainamide is an effective form of therapy for conversion of atrial fibrillation of new onset.",
author = "Fenster, {Paul E} and Comess, {Keith A.} and Randall Marsh and Charles Katzenberg and Hager, {W. David}",
year = "1983",
doi = "10.1016/0002-8703(83)90692-0",
language = "English (US)",
volume = "106",
pages = "501--504",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion

AU - Fenster, Paul E

AU - Comess, Keith A.

AU - Marsh, Randall

AU - Katzenberg, Charles

AU - Hager, W. David

PY - 1983

Y1 - 1983

N2 - We evaluated the efficacy of an intravenous infusion of procainamide in 26 consecutive candidates for cardioversion of atrial fibrillation. Procainamide was administered at a rate of 15 to 20 mg/min up to a maximum of 1000 mg. The treatment was considered effective only if cardioversion occurred during the procainamide infusion. Conversion to sinus rhythm occurred in 15 patients. Converters had a significantly shorter mean duration of atrial fibrillation (6 ± 7 days, mean ± S.D.) compared to nonconverters (79 ± 88 days) (p < 0.01). The mean left atrial size of converters (4.3 ± 0.6 cm) did not differ significantly from that of nonconverters (4.7 ± 0.9 cm). The dose of procainamide required for cardioversion ranged from 3.6 to 16.4 mg/kg. Two patients developed nonsustained ventricular tachycardia, and there was one episode of bifascicular block during the infusion. Intravenous procainamide is an effective form of therapy for conversion of atrial fibrillation of new onset.

AB - We evaluated the efficacy of an intravenous infusion of procainamide in 26 consecutive candidates for cardioversion of atrial fibrillation. Procainamide was administered at a rate of 15 to 20 mg/min up to a maximum of 1000 mg. The treatment was considered effective only if cardioversion occurred during the procainamide infusion. Conversion to sinus rhythm occurred in 15 patients. Converters had a significantly shorter mean duration of atrial fibrillation (6 ± 7 days, mean ± S.D.) compared to nonconverters (79 ± 88 days) (p < 0.01). The mean left atrial size of converters (4.3 ± 0.6 cm) did not differ significantly from that of nonconverters (4.7 ± 0.9 cm). The dose of procainamide required for cardioversion ranged from 3.6 to 16.4 mg/kg. Two patients developed nonsustained ventricular tachycardia, and there was one episode of bifascicular block during the infusion. Intravenous procainamide is an effective form of therapy for conversion of atrial fibrillation of new onset.

UR - http://www.scopus.com/inward/record.url?scp=0020557283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020557283&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(83)90692-0

DO - 10.1016/0002-8703(83)90692-0

M3 - Article

C2 - 6881022

AN - SCOPUS:0020557283

VL - 106

SP - 501

EP - 504

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -